'eClinical Dialogues' to Bring Informative Industry News, Trends and Topics
Directly to the Desktop
CLEVELAND, Dec. 18 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported that it has launched a new initiative involving a continuous series of educational and innovative webcasts. Delivered via email approximately twice a month, and also residing on the Company's website in a library format for convenient viewing, 'eClinical Dialogues' will feature DATATRAK professionals discussing critical issues and advancements that affect the use of technology in today's worldwide clinical trials market. The targeted audience for these webcasts includes the Company's customer and investor markets, as the topics covered will be informative and applicable to both constituencies.
"Our goal is to provide timely, relevant topics of interest to professionals involved in all aspects of clinical trials and to be able to deliver the messages in an innovative and efficient format," said Dr. Jeffrey A. Green, President and Chief Executive Officer, DATATRAK International Inc. "This new webcast venue is unique in our market, allowing us to share information in a medium that is both interactive and convenient. Viewers can simply click on a link in the email or visit our website for a complete library of topics."
Webcast content will be updated regularly and will include information
on some of the following issues:
-- Reality of Adaptive Trials
-- Incorporating Imaging into Clinical Investigations
-- Differentiating integrated versus unified eClinical technology
In addition, these webcasts will also be used to disseminate breaking DATATRAK news on an as-needed basis as with the recent announcement of the relationship between NTT DATA Corporation of Japan and DATATRAK.
The DATATRAK eClinical Dialogues can be viewed or replayed at any time. Other interactive features include the option to submit questions, comments or suggestions for ongoing or future expansions on any topic. Please visit http://www.datatrak.net to view current webcasts, or for additional information.
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 17 drugs and devices that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.
|SOURCE DATATRAK International, Inc.|
Copyright©2007 PR Newswire.
All rights reserved